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Supplementary Table 1. Cohort Information & Quality Control Details 
 
Cohort  LADA, T1D, T2D, or 
population controls 
Population Details N Genotyping chip Genotyping QC Imputation 
QC 
ActionLada LADA British, German Aged 30-70 Patients were designated with diabetes 
according to standard criteria, and LADA was defined as 
follows: patients 1) aged 30–70 years, 2) with diabetes 
associated autoantibodies, and 3) who did not require 
insulin treatment for at least 6 months post diagnosis. 
Only samples of European ancestry were included. 
Cohort overlaps with Cousminer DL et al. Diabetes Care 
(2018) 
1051 Illumina Infinium II 
Omni Express 
Individuals with ambiguous sex, genotype 
missingness > 5%, and relatedness (pi_hat > 0.2) 
were excluded. PCA was performed to exclude 
individuals of non-European ancestry. 
MAF <0.01 
ActionLada 'Plus' LADA American and British LADA was defined as follows: patients 1) aged 30–70 
years, 2) with diabetes associated autoantibodies, and 3) 
who did not require insulin treatment for at least 6 
months post diagnosis. A description of participants and 
study design can be found in Hawa MI et al. Diabetes 
Care (2013). More details such as exclusion criteria, etc 
can be found in Cousminer DL et al. Diabetes Care (2018) 
441 Illumina Infinium II 
Omni Express 
Individuals with ambiguous sex, genotype 
missingness > 5%, and relatedness (pi_hat > 0.2) 
were excluded. PCA was performed to exclude 






Population controls American of diverse ethnic 
backgrounds 
Samples of European descent only were included. More 
details such as recruitment,  exclusion criteria, etc can be 
found in Cousminer DL et al. Diabetes Care (2018) 
1296 Illumina Infinium II 
Omni Express 
Individuals with  ambiguous sex, genotype 
missingness > 5%, and relatedness (pi_hat > 0.2) 
were excluded. PCA was performed to exclude 





Population controls USA, Multiple European 
countries, Australia 
More details such as recruitment, inclusion and exlusion, 
etc can be found in Berndt et al  
1683 Illumina Omni 
Express 
Individuals with  genotype missingness > 5%  were 
excluded. PCA was performed to exclude individuals 





1958 British Birth 
Control Cohort 
England, Scotland and Wales More details such as recruitment, inclusion and exclusion 
criteria, etc can be found in WTCCC Nature (2007) 
3000 Illumina 1.2 M Individuals with  ambiguous sex, genotype 
missingness > 5%, and duplicates and relatedness 
(pi_hat > 0.2)  were excluded. PCA was performed to 
exclude individuals of non-European ancestry.Single 
nucleotide polymorphisms (SNPs) with a call rate 
<95%, Hardy-Weinberg equilibrium P<10-5 and with 
A/T and G/C alleles were removed.  
MAF <0.01 
T1D England, Scotland and Wales More details such as recruitment, inclusion and exclusion 
criteria, etc can be found in WTCCC Nature (2007). Type 
1 diabetes cases were insulin dependent since diagnosis, 
with a minimum period of at least 6 months, and an age 
of diagnosis below 17 years. 
2000 Affymetrix 500 M Individuals with ambiguous sex, genotype 
missingness > 5%, and rduplicates  were excluded. 
PCA was performed to exclude individuals of non-
European ancestry.Single nucleotide polymorphisms 
(SNPs) with a call rate <95%, Hardy-Weinberg 
equilibrium P<10-5 and with A/T and G/C alleles were 
removed.  
MAF <0.01 
T2D England, Scotland and Wales More details such as recruitment, inclusion and exclusion 
criteria, etc can be found in WTCCC Nature (2007) 
1999 Affymetrix 500 M Individuals with  ambiguous sex, duplicates, and 
genotype missingness > 5%. PCA was performed to 
exclude individuals of non-European ancestry.Single 
nucleotide polymorphisms (SNPs) with a call rate 
<95%, Hardy-Weinberg equilibrium P<10-5 and with 








LADA Scania, Sweden ANDIS:  GAD (ELISA: Negative:< 5 U/ml, Positive:=> 10 
U/ml, RIA: Negative:0-34 U/ml, Positive:> 50 U/ml); 
LADA: Age at onset ≥ 35 years, GAD (ELISA) > 10 kE/L, 
GAD (RIA) >50 U/ml, Cohort reference: 
http://andis.ludc.med.lu.se/; SDR: GAD (Wallenberg lab 
(AU ref < 5.0), GAD (Wallenberg lab (IU/ml ref <32); 
LADA: Age at onset ≥ 35, GAD ≥ 10 AU, GAD ≥ 50 IU/ml, 
For patients that did not fulfill the criteria for any of the 
above, the diagnosis given by their physician was used, 
Cohort reference: Lindholm E, Agardh E, Tuomi T, Groop 
L, Agardh CD. Classifying diabetes according to the new 
WHO clinical stages. Eur J Epidemiol. 2001;17(11):983-9. 
Epub 2002/10/17 
823 Illumina Infinium 
Omni Express Exome 
Exclude individuals:  
Call rate < 95%;  
ambiguous gender;  
genome-wide heterozygosity (3 SD from mean);  
duplicates or related individuals (pi-hat >= 0.2);  
average pi-hat outliers;  
population outliers. 
Exclude SNPs:  
monomorphic;  
(MAF >= 0.05 and SNP missing rate > 0.05);  
(MAF < 0.05 and SNP missing rate > 0.01);  
(MAF >= 0.05 and HWE <= 0.00000057);  




T1D Scania, Sweden GAD (Wallenberg lab (AU ref < 5.0), GAD (Wallenberg lab 
(IU/ml ref <32), C-peptide (Klin kem (RIA) ref 0.25-0.75), 
C-peptide (Klin kem ref 0.3-1.3), C-peptide (Lund (ref 
0.25-0.75); T1D: Age  at onset < 35, GAD ≥ 20 AU, GAD ≥ 
100 IU/ml, C-peptide ≥ 0.25 (Klin kem (RIA)), C-peptide ≥ 
0.3 (Klin kem), C-peptide ≥ 0.25 (Lund), For patients that 
did not fulfill the criteria for any of the above, the 
diagnosis given by their physician was used, Cohort 
reference: Lindholm E, Agardh E, Tuomi T, Groop L, 
Agardh CD. Classifying diabetes according to the new 
WHO clinical stages. Eur J Epidemiol. 2001;17(11):983-9. 
Epub 2002/10/17 
656 Illumina Infinium 
Omni Express 
Exclude individuals:  
Call rate < 95%;  
ambiguous gender;  
genome-wide heterozygosity (3 SD from mean);  
duplicates or related individuals (pi-hat >= 0.2);  
average pi-hat outliers;  
population outliers. 
Exclude SNPs:  
monomorphic;  
(MAF >= 0.05 and SNP missing rate > 0.05);  
(MAF < 0.05 and SNP missing rate > 0.01);  
(MAF >= 0.05 and HWE <= 0.00000057);  
(MAF < 0.05 and HWE <= 0.0001) 




Population controls Malmö, Sweden More details such as recruitment, inclusion and exclusion 
criteria, etc can be found in Rosvall M, Persson M, Ostling 
G, et al. Risk factors for the progression of carotid intima-
media thickness over a 16-year follow-up period: the 
Malmo Diet and Cancer Study. Atherosclerosis. Apr 
2015;239(2):615-621. 
3218 Illumina Infinium 
Omni Express Exome  
Exclude individuals:  
Call rate < 95%;  
ambiguous gender;  
genome-wide heterozygosity (3 SD from mean);  
duplicates or related individuals (pi-hat >= 0.2);  
population outliers. 
Exclude SNPs:  
monomorphic;  
SNP missing rate > 0.05;  







Supplementary Table 2. Power Calculation to detect significant signals in LADA cohort 
 
Assumptions multiplicative model (log additive model) for non-MHC Class II signals, Significance level: 0.00000883,LADA cases=1428, 









Disease allele frequency 3 2 1.8 1.6 1.4 1.35 
0.01 89.70% 14.50% 5.30% 1.30% 0.20% 0.10% 
0.03 100% 90.90% 64.90% 25.80% 3.80% 1.90% 
0.05 100% 99.80% 95.60% 65.10% 14.70% 7.60% 
0.1 100% 100% 100% 98.50% 58.10% 37.60% 
0.2 100% 100% 100% 100% 95.40% 84.30% 
0.3 100% 100% 100% 100% 99.4% 95.9% 
Supplementary Table 3. Independent association signals from the conditional analysis in type 1 
diabetes cases vs WTCCC controls. 
 
Conditional P-value, beta, and standard error(SE) are calculated from stepwise regression conditional on all SNP/HLA-Alleles in rows 
above (first column) in 1985 type 1 diabetes cases vs. 2219 controls. *Conditional P-value from stepwise regression conditional on all 
SNPs/HLA-Alleles (column 1) in rows above. Position is base pair position according to build 36 of the human genome reference. 
Linkage disequilibrium (LD) (r2) is between the SNP/HLA allele and most significant (top) classical HLA allele. “P” in the allele column 
indicates that the HLA allele is present and “A” indicates absent.A*24 did not reach significance after conditioning on all variants in 






















Cases Controls P-value Beta SE 
rs3957146 HLA-DQA2 32789508 T/C 0.385 0.113 4.91 (4.39- 5.50) 8.94E-165 8.94E-165 1.44 0.05 DQB1*0302 0.99 
DQB1*0201 HLA-DQB1 32739039 A/P 0.338 0.140 3.13 (2.81-3.49) 1.02E-91 7.98E-153 1.56  0.06 DQB1*0201 1.00 
rs9268633 HLA-DRA 32514451 A/G 0.017 0.197 0.07 (0.06-0.09) 5.94E-132 5.62E-53 -1.46 0.10 DRB1*1501 0.59 
rs1610649 HLA-G 29876896 A/G 0.384 0.418 0.87 (0.79-0.94) 5.59E-04 6.89E-23 -0.61  0.06 B*39  0.00 
B*39 HLA-B 31431272 A/P 0.043 0.016 2.73 (2.07-3.62) 1.82E-12 1.06E-15 1.36 0.17 B*39 1.00 
DRB1*0404 HLA-DRB1 32660042 A/P 0.082 0.048 1.75 (1.47-2.09) 5.47E-09 6.17E-15 1.04 0.13 DRB1*0404 1.00 
rs17427599 HLA-DQB1 32775342 C/T 0.151 0.245 0.55 (0.49-0.61) 2.16E-23 7.97E-12 -0.59 0.09 DPB1*0402 0.00 
rs2301225 HLA-DPA1 33143838 C/T 0.059 0.109 0.51 (0.44-0.60) 1.07E-16 9.56E-12 -0.72  0.11 DPB1*0402 0.96 
rs397081 NOTCH4 32300595 T/C 0.095 0.045 2.22 (1.86-2.65) 2.20E-18 1.11E-10 0.79  0.12 A*3201 0.00 
rs9262545 MUC22 31101041  G/A 0.087 0.119 0.70 (0.61 -0.81) 4.89E-06 7.83E-11 -0.67 0.11 A*3201 0.00 
rs9262547 MUC22 31101206 T/A 0.135 0.119 1.16 (1.02-1.32) 0.034 7.17E-17 1.59 0.19 A*3201 0.00 
rs9259852 HLA-A 30004400 T/C 0.023 0.041 0.55 (0.43-0.72) 3.04E-06 2.04E-08 -1.00  0.18 A*3201 0.96 
rs9269081 HLA-DRA 32549078 C/A 0.110 0.265 0.34 (0.30-0.39) 1.19E-62 1.61E-07 -0.57 0.11 DQB1*0602 0.00 
rs1978029 HLA-DQB2 32839688  T/C 0.349 0.463 0.62 (0.57-0.68) 2.53E-22 1.92E-06 -0.36 0.08 A*24 0.00 
 Supplementary Table 4. Independent association signals from the conditional analysis in LADA 
cases vs controls. 
 
Conditional P-value, beta, and standard error(SE) are calculated from stepwise regression conditional on all SNP/HLA-alleles in rows 
above (first column) in 1428 LADA cases vs. 2979 controls. Conditional P-value from stepwise regression conditional on all SNPs/HLA-
Alleles (column 1) in rows above. Position is base pair position according to build 36 of the human genome reference. LD (r2) is 
between the SNP/HLA allele and the most significant (top) classical HLA allele. “P” in the allele column indicates the HLA allele is 
present and “A” indicates absent. ^DPB1*0402 did not reach significance after conditioning on all variants in the first column. For 























Cases Controls P-value* Beta SE 
rs3957146 HLA-DQA2 32789508 T/C 0.251 0.101 3.03 (2.63-3.33) 1.80E-68 1.80E-68 1.14 0.06 DQB1*0302 0.99 
DRB1*03 HLA-DRB1 32660042 A/P 0.209 0.118 1.99 (1.76-2.24) 5.31E-35 3.23E-52 1.07 0.07 DRB1*03 1 
rs9269081 HLA-DRA 32549078 C/A 0.179 0.315 0.47 (0.42 -0.53) 1.40E-42 3.54E-16 -0.49 0.06 DQB1*0604 0.01 
DRB1*0404 HLA-DRB1 32660042 A/P 0.037 0.035 1.04 (0.82-1.33) 0.328084 3.08E-11 0.95 0.14 DRB1*0404 1 
DQB1*0604 HLA_DQB1 32739039 A/P 0.059 0.035 1.75 (1.43-2.17) 5.73E-07 1.55E-10 0.81 0.13 DQB1*0604 1 
rs2143462 C6orf10 32443182 C/T 0.221 0.167 1.42 (1.26-1.58) 1.39E-08 8.24E-08 0.47 0.09 DPA1*02 0.01 
DPA1*02 HLA-DPA1 33145064 A/P 0.148 0.186 0.76 (0.67-0.86) 1.23E-04 1.62E-06 -0.34 0.07 DPA1*02 1 
rs3130192 HLA-DPB1 33169908 C/T 0.066 0.103 0.62 (0.52-0.73) 3.96E-08 5.32E-06 -0.42 0.09 ^DPB1*0402 0.85 
 Supplementary Table 5.  Independent association signals from the conditional analysis in the 
downsampled cohort of type 1 diabetes cases (n=1,428) vs controls. 
 
Conditional P-value calculated from stepwise regression conditional on all SNP/HLA-alleles in rows above (first column) in 1428 type 
1 diabetes cases versus 2219 controls. Shaded rows denote that this MHC Class I signal appeared in the full type 1 diabetes vs 
WTCCC dataset but not in LADA vs control set. *rs1619379 is in LD with rs1610649 (r2=0.822), which is consistent in the full type 1 
diabetes vs WTCCC dataset. “P” in the allele column indicates the HLA allele is present and “A” indicates absent. ^C*07 did not reach 







Minor Allele Frequency Odds Ratio  Single Marker  Conditional Top Classical  LD  
Allele Cases Controls (95% CI) P-value P-value* Beta Standard Error HLA allele  (r2) 
rs3957146 HLA-DQA2 32789508 T/C 0.39 0.113 5.02 (4.45-5.66) 2.98E-157 2.98E-157 1.57 0.06 DQB1*0302 0.99 
DQB1*0201 HLA-DQB1 32739039 A/P 0.338 0.14 3.14 (2.80-3.528) 7.33E-81 3.27E-136 1.67 0.07 DQB1*0201 1 
rs9268633 HLA-DRA 32514451 G/A 0.02 0.197 0.08 (0.06-0.11) 6.40E-102 2.02E-37 -1.35 0.11 DQB1*0602  0.53 
rs1619379 HLA-G 29893214 G/A 0.398 0.432 0.87 (0.79-0.95) 0.002 1.37E-17 -0.56 0.07 DRB1*0404 0 
DRB1*0404 HLA-DRB1 32660042 A/P 0.083 0.048 1.78 (1.47-2.15) 1.54E-08 9.91E-13 0.98 0.14 DRB1*0404 1 
B*39 HLA-B 31431272 A/P 0.043 0.016 2.79 (2.08-3.75) 5.09E-12 5.58E-14 1.43 0.19 B*39 1 
rs2301225 HLA-DPA1 33143838 C/T 0.057 0.109 0.49 (0.41-0.59) 1.60E-14 3.96E-12 -0.81 0.12 DPB1*0402 0.96 
rs9267665 C2 31978835 C/T 0.082 0.03 2.92 (2.35-3.64) 1.86E-21 1.73E-09 0.88 0.15 DQB1*0602 0 
rs9269081 HLA-DRA 32549078 C/A 0.11 0.265 0.34 (0.30-0.39) 1.60E-54 1.79E-13 -0.8 0.11 DQB1*0602 0.31 
rs9262545 MUC22 31101041 G/A 0.087 0.119 0.70 (0.60-0.82) 8.07E-06 3.36E-09 -0.67 0.11 A*24 0 
rs9262547 MUC22 31101206 T/A 0.133 0.119 1.13 (0.98-1.31) 0.16388 9.69E-14 1.64 0.22 B*14 0 
rs549182 NOTCH4 32313023 G/A 0.074 0.02 3.93 (3.05-5.06) 5.59E-28 1.20E-06 1.33 0.27 B*14 0 
rs2853928 HLA-C 31365490 G/T 0.372 0.295 1.42 (1.28-1.57) 3.22E-11 1.26E-06 0.48 0.1 ^C*07 0.79 
 
  
Supplementary Table 6.  Independent association signals from the conditional analysis in the 
downsampled cohort of type 1 diabetes cases (n=714) vs controls.  
 
Conditional P-value calculated from stepwise regression conditional on all SNP/HLA-alleles in rows above (first column) in 714 type 1 
diabetes cases versus 2219 controls. Shaded rows denote that this MHC Class I signal appeared in the full type 1 diabetes vs WTCCC 
dataset but not in LADA vs control set. “P” in the allele column indicates the HLA allele is present and “A” indicates absent. 
^DPB1*0402 did not reach significance after conditioning on all variants in the first column. 
 
SNP/HLA-
Allele Locus Position 





Conditional  Top Classical 
HLA allele 
LD 
(r2) (Major /Minor) Cases Controls P-value Beta SE 
rs3957146 HLA-DQA2 32789508 T/C 0.399 0.112 5.25 (4.55-6.06) 3.69E-112 3.69E-112 1.75 0.08 DQB1*0302 0.99 
rs2187668  HLA-DQA1 32713862 G/A 0.319 0.14 2.88 (2.50-3.32) 2.33E-48 6.42E-88 1.83 0.09 DRB1*0301 0.99 
rs9268633 HLA-DRA 32514451 G/A 0.014 0.197 0.06 (0.04-0.09) 1.61E-57 3.77E-24 -1.35 0.13 DRB1*1501 0.59 
B*39 HLA-B 31431272 A/P 0.047 0.015 3.20 (2.26-4.53) 1.26E-10 4.75E-15 1.94 0.25 B*39 1 
DRB1*0404 HLA-DRB1 32660042 A/P 0.076 0.049 1.62 (1.27-2.06) 1.68E-04 1.23E-13 1.19 0.16 DRB1*0404 1 
rs1610649 HLA-G 29876896 A/G 0.374 0.418 0.83(0.74-0.83) 0.002 2.17E-12 -0.6 0.09 DPB1*0402 0 
rs9262545 MUC22 31101041 G/A 0.08 0.119 0.64 (0.52-0.80)  1.57E-05 2.81E-08 -0.72 0.13 DPB1*0402 0 
rs2249168 MUC21 31066233 C/T 0.131 0.124 1.06 (0.89-1.27) 0.81 2.65E-09 1.38 0.23 ^DPB1*0402 0 
 
  
Supplementary Table 7.  Independent association signals from the conditional analysis in a sample 
of randomly selected type 1 diabetes and type 2 diabetes cases vs controls.  
 
Conditional P-value calculated from stepwise regression conditional on all SNP/HLA-alleles in rows above (first column) in 714 type 1 
diabetes cases + 714 type 2 diabetes cases versus 2219 controls. Shaded rows highlight the MHC Class I signals that appear in the full 
type 1 diabetes vs WTCCC conditional analysis. “P” in the allele column indicates that the HLA allele is present and “A” indicates 
absent. ^B*39 did not reach significance after conditioning on all variants in the first column. 
 
SNP/HLA-
Allele Locus Position Allele (Major /Minor) 





Conditional  Top Classical 
HLA allele 
LD 
(r2) Cases Controls P-value Beta Standard Error 
rs3957146 HLA-DQA2 32789508 T/C 0.256 0.112 2.72 (2.40-3.09) 1.16E-52 1.16E-52 0.99 0.07 DQB1*0302 0.99 
rs2187668 HLA-DQA1 32713862 G/A 0.234 0.14 1.88 (1.66-2.12) 2.71e-27  1.03E-38 0.89 0.07 DRB1*0301 0.99 
DRB1*0404 HLA-DRB1 32660042 A/P 0.059 0.049 1.22 (0.99-1.51) 0.075 2.11E-10 0.85 0.13 DRB1*0404 1 
rs1619379 HLA-G 29893214 G/A 0.4 0.43 0.88(0.800.97) 0.014 1.60E-07 -0.3 0.06 B*39 0 
rs9262545 MUC22 31101041 G/A 0.083 0.119 0.67 (0.57-0.79) 3.43E-07 6.42E-07 -0.44 0.09 B*39 0 
rs9262547 MUC22 31101206 T/A 0.117 0.118 0.99 (0.85-1.14) 0.548 3.03E-16 1.63 0.2 B*39 0 
HLA_B_39 HLA-B 31431272 A/P 0.03 0.015 1.99 (1.44-2.77) 4.73E-05 2.61E-06 0.88 0.19 ^B*39 1 
  
Supplementary Table 8. Independent association signals from the conditional analysis in type 1 
diabetes vs controls in the Swedish replication cohort.  
 
Conditional P-value calculated from stepwise regression conditional on all SNP/HLA-Alleles in rows above (first column) in 656 type 1 diabetes cases 
versus 3218 controls. Position is base pair position according to build 36 of the human genome reference. Shaded rows denote this signal appeared in 
the full type 1 diabetes vs WTCCC dataset. LD (r2) is between the  SNP/HLA allele and top classical HLA allele. “P” in the allele column indicates the HLA 
allele is present and “A” indicates absent. ^DQB1*0503 did not reach significance after conditioning on all variants in the first column. 
 
SNP/HLA- 




Minor Allele Frequency Odds Ratio  Single 
Marker P-
value 
Conditional Top Classical  





rs9275206 HLA-DQA1 32765543 A/G 0.393 0.147 3.70 (3.33-4.34) 6.35E-89 6.35E-89 1.57 0.08 DQB1*0302 0.99 
DQB1*0201 HLA-DQB1 32739039 A/P 0.312 0.129 3.07 (2.67-3.52) 2.17E-58 1.96E-135 1.98 0.08 DQB1*0201 1 
DQB1*0602 HLA-DQB1 32739039 A/P 0.005 0.138 0.03 (0.02-0.07) 2.41E-43 1.85E-40 -1.26 0.09 DQB1*0602 1 
rs9269081 HLA-DRA 32549078 C/A 0.076 0.262 0.23(0.19-0.29) 1.60E-45 1.99E-30 -0.82 0.07 DRB1*0401 0.06 
rs3129871 HLA-DRA 32514320 C/A  0.095 0.335 0.21(0.17-0.25) 1.27E-65 3.33E-22 -0.63 0.07 DRB1*0401 0.06 
rs9784758 TAP2 32896489 T/C 0.212 0.091 2.70(2.27-3.13) 2.02E-34 1.03E-23 0.97 0.1 DRB1*0401 0.11 
rs805294 LY6G6C 31796196 C/T 0.53 0.359 2.01(1.78-2.27) 6.41E-30 8.02E-20 0.55 0.06 B*39 0 
rs707919 LY6G5B 31749118 T/C  0.333 0.31 1.11(0.98-1.27) 0.04 5.61E-16 0.42 0.05 DRB1*0401 0.13 
rs3130192 HLA-DPB1 33169908 C/T 0.049 0.107 0.43(0.33-0.56) 6.17E-10 8.83E-15 -0.77 0.1 DPB1*0402 0.88 
rs11969522 PSMB9 32967803 G/C 0.081 0.033 0.44 (0.39-0.49) 5.98E-16 6.45E-13 -1.1 0.15 B*39 0 
rs9275425 HLA-DQB1 32778852 C/A 0.487 0.293 2.22(2.04-2.56) 1.33E-40 2.54E-12 0.37 0.05 B*39 0.01 
rs1053924 PRRT1 32228693 G/A  0.144 0.305 0.38(0.32-0.45) 1.16E-32 8.02E-11 -0.43 0.07 B*39 0 
B*39 HLA-B 31431272 A/P 0.034 0.013 2.75(1.90-3.98) 6.80E-09 1.74E-10 1.54 0.24 B*39 1 
rs2735028  HLA-G 29893517 G/A 0.319 0.335 0.93(0.82-1.05) 0.315203 1.10E-09 -0.39 0.06 A*0101 0.42 
rs3104407 HLA-DQA2 32790430 A/G 0.244 0.457 0.38(0.33-0.44) 5.10E-45 3.01E-10 -0.36 0.06 DRB1*0401 0.12 
rs3104406 HLA-DQA2 32790421 G/A 0.143 0.339 0.33(0.28-0.38) 2.23E-39 9.71E-11 -0.37 0.06 DQB1*0301 0.11 
rs2239803 HLA-DRA 32519811 G/A 0.543 0.436 1.54(1.37-1.72) 3.33E-13 3.67E-09 0.32 0.05 DQB1*0503 0.01 
rs3117099 BTNL2 32466248 C/T  0.361 0.246 1.73(1.53-1.97) 3.29E-17 7.95E-11 0.35 0.05 DQB1*0604 0.06 
rs549182 NOTCH4 32313023 G/A 0.04 0.017 2.44(1.75-3.41) 9.09E-09 1.37E-06 0.97 0.2 DQB1*0503 0.01 
rs3135392 HLA-DRA 32517220 G/T  0.446 0.417 1.13(1.00-1.27) 0.04 3.23E-07 0.15 0.03 DRB1*0401 0.15 
rs3132132 HLA-DMB 33009912 G/A  0.082 0.116 0.68(0.55-0.84) 6.15E-04 1.81E-06 -0.46 0.1 DRB1*0401 0.01 
rs3129727 HLA-DQA2 32787668 C/T  0.001 0.021 0.04(0.01-0.26) 1.44E-06 7.31E-06 -1.09 0.24 ^DQB1*0503 0.99 
  
Supplementary Table 9.  Independent association signals from the conditional analysis in LADA vs 
controls in the Swedish replication cohort.  
 
Conditional P-value calculated from stepwise regression conditional on all SNP/HLA-Alleles in rows above (first column) in 823 LADA 
cases versus 3211 controls. “P” in the allele column indicates the HLA allele is present and “A” indicates absent. The HLA-B*39 

















HLA allele LD (r2) 
HLA-B*39 rs1619379 (HLA-G) 
 Cases Controls P-value* Beta Standard Error P-value Beta SE P-value Beta SE 
rs3129882    HLA-DRA 32517508 A/G 0.223 0.378 0.47(0.42-0.54) 3.51E-10 3.51E-10 -0.84 0.13 DRB1*15 0.2 0.2 
0.50
7 0.396 0.764 
0.03
9 0.13 
rs2596560  MICA 31463297 A/G 0.586 0.747 0.48 (0.43-0.53) 3.67E-08 4.19E-07 -0.67 0.13 DQB1*0201 0.35 0.122 0.61 0.395 0.52 
0.08
2 0.13 
 
